Baird raised the firm’s price target on Insulet (PODD) to $360 from $350 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which reaccelerating growth and a growing competitive advantage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet price target raised to $350 from $330 at RBC Capital
- Insulet price target raised to $353 from $331 at Canaccord
- Insulet Corporation Reports Strong Q2 2025 Growth
- Insulet’s Earnings Call Highlights Robust Growth and Optimism
- Insulet’s Strong Financial Performance and Optimistic Outlook Justify Buy Rating